Printer Friendly

Wamberg Genomic Advisors names new managing director.

M2 PHARMA-October 5, 2018-Wamberg Genomic Advisors names new managing director

(C)2018 M2 COMMUNICATIONS

Wamberg Genomic Advisors, a company involved in genomic testing, has named David Stertzer as its new managing director, it was reported yesterday.

Stertzer is the immediate past CEO and current advisor of AALU, an organisation involved in life insurance and annuities distribution in Washington, DC As the top officer at AALU for nearly thirty-three years, Stertzer is claimed to have provided continuity, leadership and strategic vision to AALU's board of directors.

In the new role, Stertzer will advise life insurance companies on genomic and advanced DNA program strategies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 5, 2018
Words:113
Previous Article:ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets.
Next Article:Boston Pharmaceuticals signs licensing and equity agreement with Novartis.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |